Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo

Journal of Virology

Volumn 71, Issue 7, 1997, Pages 5189-5196

  Wadsworth, Samuel C ^a   Zhou, Heshan ^b   Smith, Alan E ^a   Kaplan, Johanne M ^a  

^a GENZYME CORPORATION   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BLOOD CLOTTING FACTOR 9; ERYTHROPOIETIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE TARGETING; IMMUNOGENICITY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIRUS RECOMBINANT;

EID: 0030910842     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.7.5189-5196.1997     Document Type: Article

References (26)

1. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93:4102-4107.
2. Barr, D. J. Tubb, D. Ferguson, A. Scaria, A. Lieber, C. Wilson, J. Perkins, and M. A. Kay. 1995. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2:151-155.
3. Brantly, M., T. Nukiwa, and R. G. Crystal. 1988. Molecular basis of alpha-1-antitrypsin deficiency. Am. J. Med. 84(Suppl. 6A):13-31.
4. Connelly, S., J. M. Gardner, R. M. Lyons, A. McClelland, and M. Kaleko. 1996. Sustained expression of therapeutic levels of human factor VIII in mice. Blood 87:4671-4677.
5. Devinoy, E., D. Thepot, M. G. Stinnakre, M. L. Fontaine, H. Grabowski, C. Puissant, A. Pavirani, and L. M. Houdebine. 1994. High level production of human growth hormone in the milk of transgenic mice: the upstream region of the rabbit whey acidic protein (WAP) gene targets transgene expression to the mammary gland. Transgenic Res. 3:79-89.
6. Gooding, L. R. 1977. Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells. J. Immunol. 118:920-927.
7. Gooding, L. R. 1979. Specificities of killing by T lymphocytes generated against syngeneic SV40 transformants: studies employing recombinants within the H-2 complex. J. Immunol. 122:1002-1008.
8. Jaffe, H. A., C. Danel, G. Longenecker, M. Metzger, Y. Setoguchi, M. A. Rosenfeld, T. W. Gant, S. S. Thorgeirsson, L. D. Stratford-Perricaudet, M. Perricaudet, A. Pavirani, J.-P. Lecocq, and R. G. Crystal. 1992. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat. Genet. 1:372-378.
9. Kaplan, J. M. D. Armentano, T. E. Sparer, S. G. Wynn, P. A. Peterson, S. C. Wadsworth, K. K. Couture, S. E. Pennington, J. A. St. George, L. R. Gooding, and A. E. Smith. 1997. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8:45-56.
10. Kozarsky, K. E., K. Jooss, M. Donahee, J. E. Strauss III, and J. M. Wilson. 1996. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat. Genet. 13:54-62.
11. - adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther. 2:256-262.
12. Li, Q., M. A. Kay, M. Finegold, L. D. Stratford-Perricaudet, and S. L. C. Woo. 1993. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4:403-409.
13. Poller, W., S. Schneider-Rasp, U. Liebert, F. Merklein, P. Thalheimer, A. Haack, R. Schwaab, C. Schmitt, and H.-H. Brackmann. 1996. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Ther. 3:521-530.
14. Ponder, K. P., S. Gupta, F. Leland, G. Darlington, M. Finegold, J. DeMayo, F. D. Ledley, J. R. Chowdhury, and S. L. C. Woo. 1991. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc. Natl. Acad. Sci. USA 88:1217-1221.
15. Quantin, B., L. D. Perricaudet, S. Tajbakhsh, and J.-L. Mandel. 1992. Adenovirus as an expression vector in muscle cells in vivo. Proc. Natl. Acad. Sci. USA 89:2581-2584.
16. Rawle, F. C., A. E. Tollefson, W. S. Wold, and L. R. Gooding. 1989. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K. J. Immunol. 143:2031-2037.
17. Rich, D. P., L. A. Couture, L. M. Cardeza, V. M. Guiggio, D. Armentano, P. C. Espino, K. Hehir, M. J. Welsh, A. E. Smith, and R. J. Gregory. 1993. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum. Gene Ther. 4:461-476.
18. Smith, T. A. G., M. G. Mehaffey, D. B. Kayda, J. M. Saunders, S. Yei, B. C. Trapnell, A. McClelland, and M. Kaleko. 1993. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet. 5:397-402.
19. Thepot, D., E. Devinoy, M. L. Fontaine, M. G. Stinnakre, M. Massoud, G. Kann, and L. M. Houdebine. 1995. Rabbit whey acidic protein gene upstream region controls high-level expression of bovine growth hormone in the mammary gland of transgenic mice. Mol. Reprod. Dev. 42:261-267.
20. Tripathy, S. K., H. B. Black, E. Goldwasser, and J. M. Leiden. 1996. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2:545-550.
21. Wilburn, B., J. Williams, and Y. Echelard. Unpublished data.
22. Wold, W. S. M., and L. R. Gooding. 1989. Adenovirus region E3 proteins that prevent cytolysis by cytotoxic T cells and tumor necrosis factor. Mol. Biol. Med. 6:433-452.
23. Yang, Y., H. C. J. Ertl, and J. M. Wilson. 1994. MHC class I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice transfected with E1 deleted recombinant adenoviruses. Immunity 1:433-442.
24. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
25. Yang, Y., Q. Li, H. C. J. Ertl, and J. M. Wilson. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004-2015.
26. Zhou, H., W. O'Neal, N. Morral, and A. L. Beaudet. 1996. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J. Virol. 70:7030-7038.